US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALPHA COGNITION INC

5.04

-0.0200-0.40%

Post-market: 5.200.1600+3.17%19:40 EDT

Volume:61.85K

Turnover:322.56K

Market Cap:80.74M

PE:-2.50

High:5.55

Open:5.09

Low:5.04

Close:5.06

Loading ...

Overview Company News Filings

Alpha Cognition secures additional patent for Zunveyl from USPTO

BRIEF-Alpha Cognition Secures Additional U.S. Patent For Zunveyl (Benzgalantamine)

Alpha Cognition Secures Additional U.S. Patent for Zunveyl (Benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s Disease

THOMSON REUTERS

Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease

Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)

Myriad Genetics Introduces Online Prenatal Genetic Testing Resource

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch

Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

BRIEF-Alpha Cognition Signs $44 Million Exclusive Licensing Agreement For Zunveyl In China

Alpha Cognition Inc: Remains on Track to Launch Zunveyl in United States in Q1 2025

THOMSON REUTERS

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of Zunveyl (Benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

THOMSON REUTERS

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call

BRIEF-Alpha Cognition- Files Prospectus Covering Up To 1.45 Million Common Shares That May Be Offered For Resale/Otherwise Disposed Of By Selling Stockholders

Alpha Cognition Files Secondary Stock Offering Statement

MT Newswires Live

Alpha Cognition- Files Prospectus Covering up to 1.45 Mln Common Shares That May Be Offered for Resale/Otherwise Disposed of by Selling Stockholders

THOMSON REUTERS

Alpha Cognition Announces Partial Exercise of Over-allotment Option

Alpha Cognition voluntarily delisting from Canadian Securities Exchange

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ACOG/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACOG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACOG\",,,,,undefined,":{"symbol":"ACOG","market":"US","secType":"STK","nameCN":"ALPHA COGNITION INC","latestPrice":5.04,"timestamp":1745611200000,"preClose":5.06,"halted":0,"volume":61852,"hourTrading":{"tag":"盘后","latestPrice":5.2,"preClose":5.04,"latestTime":"19:40 EDT","volume":302,"amount":1572.08,"timestamp":1745624418787},"delay":0,"floatShares":10409580,"shares":16019787,"eps":-2.019472,"marketStatus":"Market Closed","change":-0.02,"latestTime":"04-25 16:00:00 EDT","open":5.09,"high":5.55,"low":5.04,"amount":322558.118148,"amplitude":0.100791,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.019472,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":5.06,"preHourTrading":{"tag":"盘前","latestPrice":5.06,"preClose":5.16,"latestTime":"08:17 EDT","volume":10,"amount":55.480000000000004,"timestamp":1745583465786},"postHourTrading":{"tag":"盘后","latestPrice":5.2,"preClose":5.04,"latestTime":"19:40 EDT","volume":302,"amount":1572.08,"timestamp":1745624418787},"volumeRatio":0.8900029375809467},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACOG\",,,,,undefined,":{"symbol":"ACOG","floatShares":10409580,"roa":"-28.00%","roe":"-79.64%","lyrEps":-2.019472,"volumeRatio":0.8900029375809467,"shares":16019787,"dividePrice":0,"high":5.55,"amplitude":0.100791,"preClose":5.06,"low":5.04,"week52Low":3.75,"pbRate":"1.95","week52High":7,"institutionHeld":0,"latestPrice":5.04,"eps":-2.019472,"divideRate":0,"volume":61852,"delay":0,"ttmEps":-2.019472,"open":5.09,"prevYearClose":5.89,"prevWeekClose":4.12,"prevMonthClose":5.06,"prevQuarterClose":5.06,"fiveDayClose":4.12,"twentyDayClose":5.31,"sixtyDayClose":6.32},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACOG\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510372350","title":"Alpha Cognition secures additional patent for Zunveyl from USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2510372350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510372350?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:42","pubTimestamp":1739367752,"startTime":"0","endTime":"0","summary":"Alpha Cognition (ACOG) announced that the United States Patent and Trademark Office has granted a new patent titled “Coated Tablets for pH-Dependen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alpha-cognition-secures-additional-patent-for-zunveyl-from-uspto?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alpha-cognition-secures-additional-patent-for-zunveyl-from-uspto?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2510374590","title":"BRIEF-Alpha Cognition Secures Additional U.S. Patent For Zunveyl (Benzgalantamine)","url":"https://stock-news.laohu8.com/highlight/detail?id=2510374590","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510374590?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:35","pubTimestamp":1739367301,"startTime":"0","endTime":"0","summary":"BRIEF-Alpha Cognition Secures Additional U.S. Patent For Zunveyl (Benzgalantamine) Feb 12 (Reuters) - Alpha Cognition ACOG.O:ALPHA COGNITION SECURES ADDITIONAL U.S. PATENT FOR ZUNVEYL (BENZGALANTAMINE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P30WU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2510237176","title":"Alpha Cognition Secures Additional U.S. Patent for Zunveyl (Benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2510237176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510237176?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:30","pubTimestamp":1739367017,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P30WU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2510437220","title":"Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2510437220","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510437220?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:30","pubTimestamp":1739367000,"startTime":"0","endTime":"0","summary":"VANCOUVER, February 12, 2025----Alpha Cognition Inc.  , a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the United States Patent and Trademark Office  has granted a new patent titled \"Coated Tablets for pH-Dependent Release of Benzgalantamine.\". This newly issued patent strengthens Alpha Cognition’s intellectual property portfolio by covering the composition of tablet formulations of benzgalantamine, further reinforcing the Company’s existing patent protections. With this approval, ZUNVEYL has patent protection in the United States through 2044, supporting the Company’s long-term growth strategy as it prepares for commercialization.Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury , for which there are currently no app","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-secures-additional-u-133000849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACOG","BK4113","BK4139","ACI"],"gpt_icon":0},{"id":"2507675845","title":"Stonegate Capital Partners Initiates Coverage on Alpha Cognition Inc. (ACOG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2507675845","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507675845?lang=en_us&edition=fundamental","pubTime":"2025-01-31 00:05","pubTimestamp":1738253100,"startTime":"0","endTime":"0","summary":"Dallas, Texas-- - Alpha Cognition Inc. : Stonegate Capital Partners initiates their coverage on Alpha Cognition Inc. . Alpha Cognition Inc. reported significant progress in 2024 so far, marked by key financial and corporate milestones. Alpha Cognition received approval for its flagship Alzheimer's therapy ZUNVEYL , successfully raised $4.5M in financing, and completed the necessary preparations for listing on the NASDAQ exchange. These initiatives have positioned the Company to launch ZUNVEYL in 1Q25, with an in place sales force and commercial production already underway.To view the full announcement, including downloadable images, bios, and more, click here.Alpha Cognition is set to launch ZUNVEYL in 1Q25, targeting the long-term care  market, a $2 billion addressable market representing 36% of Alzheimer's prescriptions.ZUNVEYL's prodrug mechanism bypasses GI absorption, significantly reducing common side effects like nausea and insomnia, leading to better patient adherence and impro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/stonegate-capital-partners-initiates-coverage-160500121.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/stonegate-capital-partners-initiates-coverage-160500121.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","SQQQ","QLD","USAW.SI","USJW.SI","TSYW.SI","NQmain","LTC","ACOG","TQQQ","BK4588","QQQ","QID","NVIW.SI",".IXIC","BK4585","BK4139","BK4203","BK4225","PSQ"],"gpt_icon":0},{"id":"2505134580","title":"Myriad Genetics Introduces Online Prenatal Genetic Testing Resource","url":"https://stock-news.laohu8.com/highlight/detail?id=2505134580","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505134580?lang=en_us&edition=fundamental","pubTime":"2025-01-23 21:30","pubTimestamp":1737639000,"startTime":"0","endTime":"0","summary":"SALT LAKE CITY, Jan.  23, 2025  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing comprehen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/23/3014262/15459/en/Myriad-Genetics-Introduces-Online-Prenatal-Genetic-Testing-Resource.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYGN","ACOG","BK4139"],"gpt_icon":0},{"id":"2505974521","title":"OTC Markets Group Announces Quarterly Index Performance and Rebalancing","url":"https://stock-news.laohu8.com/highlight/detail?id=2505974521","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505974521?lang=en_us&edition=fundamental","pubTime":"2025-01-22 20:00","pubTimestamp":1737547200,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 22, 2025  -- OTC Markets Group Inc. , operator of regulated financial markets for 12,000 U.S. and global securities, today announced the fourth quarter 2024 performance and quarterly rebalancing of the OTCQX and OTCQB indexes, including the OTCQX Canada Index and the OTCQX Dividend Index.The OTCQX Composite Index , a benchmark for the overall OTCQX Best Market, was down 9.8% in Q4 2024. 32 new companies joined the Index while 31 companies were removed. Aduro Clean Technologies  went to NASDAQ on 11/7/2024. Mackenzie Realty Capital  went to NASDAQ on 11/11/2024. Exodus Movement  went to NYSE MKT on 12/18/2024.The OTCQX Billion+ Index , which tracks the performance of $1 billion-plus market cap OTCQX companies was down 10.0% in Q4 2024. 6 new companies joined the Index and 4 companies were removed.The OTCQX Dividend Index , which tracks dividend-paying U.S. and international OTCQX companies, was down 9.6% in Q4 2024. 12 new companies joined the Index, while 9 companies wer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/otc-markets-group-announces-quarterly-120000883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","USJW.SI","TSSI","BK4161","BK4139","TSYW.SI","BK4023","BHST","NVIW.SI","ADUR","USAW.SI","BK4160","OTCM","SQQQ","ACOG","QID","TZUP","BK4112","BSGM","TQQQ","QLD","MNQmain","EXOD","BK4134","MKZR","BK4137","NQmain","BK4082","ATS","PSQ",".IXIC"],"gpt_icon":1},{"id":"2505627334","title":"Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology","url":"https://stock-news.laohu8.com/highlight/detail?id=2505627334","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505627334?lang=en_us&edition=fundamental","pubTime":"2025-01-21 21:30","pubTimestamp":1737466200,"startTime":"0","endTime":"0","summary":"Study showed online screening tool and patient education improved genetic testing completion rate. SALT LAKE CITY, Jan. 21, 2025  -- Myriad Genetics, Inc. , a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The study was published in Obstetrics & Gynecology  and was highlighted in the American College of Obstetricians and Gynecologists  Daily Bulletin.“These findings further support Myriad’s commitment to provider ease of use and patient access by enabling an always-on tool to drive appropriate patient identification and education, via our Breast Cancer Risk Assessment Program,” said Melissa Gonzales, President of Women’s Health, Myriad Genetics.Myriad’s Breast Cancer Risk Assessment Program features the MyRisk with RiskScore Hereditary Cancer Test, the first and industry-leading hereditary cancer test and polygenic b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/myriad-genetics-announces-hereditary-cancer-133000725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","MYGN","ACOG"],"gpt_icon":0},{"id":"2503575308","title":"Alpha Cognition makes strategic personnel appointments to support ZUNVEYL launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2503575308","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503575308?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:50","pubTimestamp":1736862646,"startTime":"0","endTime":"0","summary":"Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alpha-cognition-makes-strategic-personnel-appointments-to-support-zunveyl-launch?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alpha-cognition-makes-strategic-personnel-appointments-to-support-zunveyl-launch?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2503573952","title":"Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL","url":"https://stock-news.laohu8.com/highlight/detail?id=2503573952","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503573952?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:30","pubTimestamp":1736861400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia & DALLAS, January 14, 2025----Alpha Cognition Inc.  , a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition’s commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer’s disease.Dr. Grady has over 30 years of experience in health care, with a strong background in both clinical practice and the life science industry. He possesses broad therapeutic experience and has supported the launch of 9 new pro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-expands-commercial-medical-133000062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4203","LTC","BK4161","B","BK4588","ACOG","BK4139","BK4225","DSI","BK4585"],"gpt_icon":0},{"id":"2501778182","title":"BRIEF-Alpha Cognition Signs $44 Million Exclusive Licensing Agreement For Zunveyl In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2501778182","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501778182?lang=en_us&edition=fundamental","pubTime":"2025-01-08 22:24","pubTimestamp":1736346281,"startTime":"0","endTime":"0","summary":"BRIEF-Alpha Cognition Signs $44 Million Exclusive Licensing Agreement For Zunveyl In ChinaJan 8  - Alpha Cognition Inc ACOG.O:ALPHA COGNITION ANNOUNCES A $44 MILLION EXCLUSIVE LICENSING AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF ZUNVEYL , AN FDA-APPROVED TREATMENT FOR MILD-TO-MODERATE ALZHEIMER’S DISEASE, IN CHINASource text: nBw7FfyWzaFurther company coverage: ACOG.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nFWN3O40IT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG","BK4139"],"gpt_icon":0},{"id":"2501722672","title":"Alpha Cognition Inc:  Remains on Track to Launch Zunveyl in United States in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2501722672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501722672?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:30","pubTimestamp":1736343001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA6XJFNQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACOG","BK4139"],"gpt_icon":0},{"id":"2501672269","title":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of Zunveyl (Benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2501672269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501672269?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:30","pubTimestamp":1736343001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA6XJFNQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2501727851","title":"Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2501727851","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501727851?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:30","pubTimestamp":1736343000,"startTime":"0","endTime":"0","summary":"Terms of the agreement total $44 million, which includes $6 million in total upfront payments split into tranches and development and commercial milestone payments. Additionally, ACI is eligible to receive royalties on net sales of ZUNVEYL in Asia , Australia and New Zealand. CMS will be responsible for the regulatory, development, manufacturing, and commercialization of ZUNVEYL in the licensed territories.\"We are excited to partner with CMS to distribute ZUNVEYL, an FDA-approved oral treatment for mild-to-moderate Alzheimer’s disease. The product has significant potential in China and we believe that CMS has the commitment and expertise to manage the complex regulatory and commercial landscape in these territories,\" said Michael McFadden, CEO of Alpha Cognition. \"With their strong track record of developing and commercializing CNS therapies in China, we believe CMS is the ideal partner to advance ZUNVEY’s regulatory development in a region where 50 million people are estimated to have","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-announces-44-million-133000343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACOG","LU2637428348.USD","LU1894683264.USD","BK4585","BK4139","BK4208","LU2346227817.USD","CMS","BK4588","LU1894683348.USD"],"gpt_icon":0},{"id":"2501623440","title":"Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2501623440","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501623440?lang=en_us&edition=fundamental","pubTime":"2025-01-06 21:30","pubTimestamp":1736170200,"startTime":"0","endTime":"0","summary":"DALLAS, January 06, 2025----Alpha Cognition Inc.  , a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced it will host an investor update call on Tuesday, January 28th, 2025 at 4pm EST to present its commercial launch strategy for ZUNVEYL , an FDA-approved treatment for mild-to-moderate Alzheimer’s disease . The call will focus on the company’s plans to address the needs of a growing patient population within the $2 billion long-term care market in the U.S.Webcast DetailsDate: Tuesday, January 28, 2025Time: 4pm ETWebcast Registration: Click HERE to register. ZUNVEYL represents a significant advancement in Alzheimer’s care and it is only the second oral AD treatment to be approved in more than a decade. Alpha Cognition’s leadership team will provide key updates on the Q1 2025 commercial launch strategy, including market positioning, launch strategy, and long-term growth objectives. Additionally, key thought lead","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-present-q1-2025-133000382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACOG","BK4139"],"gpt_icon":0},{"id":"2500629360","title":"BRIEF-Alpha Cognition- Files Prospectus Covering Up To 1.45 Million Common Shares That May Be Offered For Resale/Otherwise Disposed Of By Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2500629360","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500629360?lang=en_us&edition=fundamental","pubTime":"2025-01-01 06:53","pubTimestamp":1735685630,"startTime":"0","endTime":"0","summary":"Alpha Cognition Inc   :   * ALPHA COGNITION- FILES PROSPECTUS COVERING UP TO 1.45 MILLION COMMON SHARES THAT MAY BE OFFERED FOR RESALE/OTHERWISE DISPOSED OF BY SELLING STOCKHOLDERSSource text:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG","BK4139"],"gpt_icon":0},{"id":"2500626920","title":"Alpha Cognition Files Secondary Stock Offering Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2500626920","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500626920?lang=en_us&edition=fundamental","pubTime":"2025-01-01 06:36","pubTimestamp":1735684602,"startTime":"0","endTime":"0","summary":"Alpha Cognition  filed a registration statement with the US Securities and Exchange Commission Tuesday covering the potential resale of up to roughly 1.45 million common shares of the company by certain stockholders from time to time.The statement covers 801,413 shares issued upon conversion of $4.5 million of convertible notes of the company and 646,253 shares issuable upon exercise of warrants that were acquired by the selling stockholders in a September private placement, Alpha Cognition said.The company said it will not receive any proceeds from the share sale by the stockholders.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2500797623","title":"Alpha Cognition- Files Prospectus Covering up to 1.45 Mln Common Shares That May Be Offered for Resale/Otherwise Disposed of by Selling Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2500797623","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500797623?lang=en_us&edition=fundamental","pubTime":"2025-01-01 06:01","pubTimestamp":1735682491,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241231:nFWN3NW037:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2492641176","title":"Alpha Cognition Announces Partial Exercise of Over-allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=2492641176","media":"Business Wire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492641176?lang=en_us&edition=fundamental","pubTime":"2024-12-17 03:56","pubTimestamp":1734378960,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia & DALLAS, December 16, 2024----Alpha Cognition Inc.  , a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten U.S. public offering  have partially exercised their over-allotment option to purchase an additional 488,506 common shares at the public offering price of US$5.75 per share for an additional US$2.8 million in gross proceeds. After giving effect to the partial exercise of the over-allotment option, the Company sold an aggregate 9,184,159 common shares for gross proceeds of approximately US$52.8 million, before deducting underwriter discounts and other related expenses. The option closing date was December 16, 2024. The common shares began trading on The Nasdaq Capital Market on November 12, 2024, under the ticker symbol \"ACOG\".Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for pa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KsjJcltVsTZHnvZnTzo.bg--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fe652bc16d53af3f3ab3a6faa8be39e1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KsjJcltVsTZHnvZnTzo.bg--~B/aD00ODA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fe652bc16d53af3f3ab3a6faa8be39e1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alpha-cognition-announces-partial-exercise-195600465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ACOG"],"gpt_icon":0},{"id":"2491536949","title":"Alpha Cognition voluntarily delisting from Canadian Securities Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2491536949","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491536949?lang=en_us&edition=fundamental","pubTime":"2024-12-13 07:45","pubTimestamp":1734047111,"startTime":"0","endTime":"0","summary":"Alpha Cognition (ACOG) will voluntarily delist its common shares from the Canadian Securities Exchange, in connection with its listing on Nasdaq. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alpha-cognition-voluntarily-delisting-from-canadian-securities-exchange?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alpha-cognition-voluntarily-delisting-from-canadian-securities-exchange?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","ACOG","BK4139","USJW.SI","NVIW.SI","USAW.SI",".IXIC","PSQ","QID","SQQQ","TSYW.SI","MNQmain","QLD","TQQQ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":43,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACOG\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-31","symbol":"ACOG","fiscalQuarterEnding":"2024/12","expectedEps":-0.48,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743393600000,"reportTimeType":"post","actualEps":-0.51}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACOG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACOG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1742356800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACOG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACOG","date":"2025-04-24","current":-5.384852,"percent":0.844037,"low":-7.19781,"twenty":-6.524853,"median":-6.13782,"eighty":-5.5123,"high":-2.141254,"avg":-5.964986,"sd":0.769029,"marketCap":78817352},"quantilePoints":[{"date":"2024-11-15","current":-5.518409,"twenty":-5.518409,"median":-5.518409,"eighty":-3.492116,"marketCap":89218230.86},{"date":"2024-11-22","current":-6.095906,"twenty":-6.0779,"median":-6.040783,"eighty":-5.518409,"marketCap":89580038.69},{"date":"2024-11-29","current":-7.052964,"twenty":-6.126453,"median":-6.040783,"eighty":-5.612398,"marketCap":103759893.65},{"date":"2024-12-06","current":-6.313396,"twenty":-6.313396,"median":-6.095906,"eighty":-5.994414,"marketCap":92879715.89},{"date":"2024-12-13","current":-5.804676,"twenty":-6.309556,"median":-6.047523,"eighty":-5.928174,"marketCap":85395665.51},{"date":"2024-12-20","current":-3.792145,"twenty":-6.289737,"median":-6.03741,"eighty":-5.564347,"marketCap":55788252.01},{"date":"2024-12-27","current":-5.520861,"twenty":-6.27191,"median":-5.988356,"eighty":-5.512882,"marketCap":81220325},{"date":"2025-01-03","current":-6.174218,"twenty":-6.276367,"median":-6.018645,"eighty":-5.517304,"marketCap":90832197},{"date":"2025-01-10","current":-6.228664,"twenty":-6.280824,"median":-6.044156,"eighty":-5.518409,"marketCap":91633187},{"date":"2025-01-17","current":-6.479118,"twenty":-6.381986,"median":-6.114998,"eighty":-5.51988,"marketCap":95317738},{"date":"2025-01-24","current":-6.827574,"twenty":-6.433383,"median":-6.156206,"eighty":-5.546995,"marketCap":100444070},{"date":"2025-01-31","current":-6.533564,"twenty":-6.529208,"median":-6.174218,"eighty":-5.650957,"marketCap":96118728},{"date":"2025-02-07","current":-6.424671,"twenty":-6.533564,"median":-6.22812,"eighty":-5.770729,"marketCap":94516749},{"date":"2025-02-14","current":-6.228664,"twenty":-6.533564,"median":-6.228664,"eighty":-5.853338,"marketCap":91633187},{"date":"2025-02-21","current":-6.860242,"twenty":-6.561876,"median":-6.283111,"eighty":-5.928174,"marketCap":100924664},{"date":"2025-02-28","current":-6.533564,"twenty":-6.583654,"median":-6.313396,"eighty":-5.93555,"marketCap":96118728},{"date":"2025-03-07","current":-5.83665,"twenty":-6.561876,"median":-6.313396,"eighty":-5.93555,"marketCap":85866063},{"date":"2025-03-14","current":-6.130661,"twenty":-6.544453,"median":-6.27751,"eighty":-5.928174,"marketCap":90191406},{"date":"2025-03-21","current":-6.043547,"twenty":-6.542275,"median":-6.261332,"eighty":-5.928174,"marketCap":88909823},{"date":"2025-03-28","current":-5.782204,"twenty":-6.533564,"median":-6.228664,"eighty":-5.862785,"marketCap":85065074},{"date":"2025-04-04","current":-5.461466,"twenty":-6.533564,"median":-6.206886,"eighty":-5.804122,"marketCap":79938742},{"date":"2025-04-11","current":-4.56399,"twenty":-6.533564,"median":-6.185107,"eighty":-5.723114,"marketCap":66802511},{"date":"2025-04-17","current":-4.651549,"twenty":-6.533564,"median":-6.172541,"eighty":-5.520861,"marketCap":68084094},{"date":"2025-04-24","current":-5.384852,"twenty":-6.524853,"median":-6.13782,"eighty":-5.5123,"marketCap":78817352}],"updateTime":1745655276403}}}